<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bicalutamide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bicalutamide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bicalutamide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11312" href="/d/html/11312.html" rel="external">see "Bicalutamide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F141227"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Casodex</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866080"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Bicalutamide;</li>
<li>APO-Bicalutamide;</li>
<li>Casodex;</li>
<li>JAMP-Bicalutamide;</li>
<li>PMS-Bicalutamide;</li>
<li>PRO-Bicalutamide-50;</li>
<li>TEVA-Bicalutamide</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F141265"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antiandrogen</li></ul></div>
<div class="block doa drugH1Div" id="F141231"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="562c2012-3943-4422-862c-4340368b07a8">Prostate cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic:</b>
<b>Oral:</b> 50 mg once daily (in combination with an LHRH analogue).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fda59d24-ff5d-4d71-8a63-9f2cc75e857c">Prostate cancer, locally advanced, high recurrence risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, locally advanced, high recurrence risk (off-label use):</b>
<b>Oral:</b> 150 mg once daily (as monotherapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16753373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16753373'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If a dose is missed, skip the missed dose and take the next dose at the next scheduled time; do not double the next dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990656"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50987872"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment at treatment initiation:</i> Mild, moderate, or severe impairment: No dosage adjustment is necessary. Use with caution in patients with moderate to severe impairment; clearance may be delayed in severe impairment (based on a limited number of patients).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment during treatment:</i> ALT &gt;2 times ULN or development of jaundice: Discontinue immediately.</p></div>
<div class="block doe drugH1Div" id="F141232"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F141199"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Adverse reaction percentages reported as part of combination regimen with an LHRH analogue unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Pain (35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (53%), gynecomastia (9%; monotherapy [150 mg]: 38% to 73% [McLeod 2006])</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (22%), nausea (15%), diarrhea (12%), abdominal pain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Mastalgia (6%; monotherapy [150 mg]: 39% to 85% [McLeod 2006]), pelvic pain (21%), hematuria (12%), nocturia (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (25%), weakness (22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">≥2% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (8%), hypertension (8%), angina pectoris (2% to &lt;5%), cardiac arrest (2% to &lt;5%), cardiac failure (2% to &lt;5%), coronary artery disease (2% to &lt;5%), edema (2% to &lt;5%), myocardial infarction (2% to &lt;5%), syncope (2% to &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (10%), paresthesia (8%), headache (7%), insomnia (7%), myasthenia (7%), anxiety (5%), chills (2% to &lt;5%), confusion (2% to &lt;5%), drowsiness (2% to &lt;5%), hypertonia (2% to &lt;5%), nervousness (2% to &lt;5%), neuropathy (2% to &lt;5%), depression (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (9%), diaphoresis (6%), alopecia (2% to &lt;5%), pruritus (2% to &lt;5%), xeroderma (2% to &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (7%), hyperglycemia (6%), weight gain (5%), decreased libido (2% to &lt;5%), dehydration (2% to &lt;5%), gout (2% to &lt;5%), hypercholesterolemia (2% to &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (7%), anorexia (6%), flatulence (6%), vomiting (6%), dysphagia (2% to &lt;5%), hernia (2% to &lt;5%), melena (2% to &lt;5%), periodontal abscess (2% to &lt;5%), xerostomia (2% to &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (9%), impotence (7%), difficulty in micturition (5%), urinary retention (5%), dysuria (2% to &lt;5%), urinary urgency (2% to &lt;5%), urinary incontinence (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Gastrointestinal carcinoma (2% to &lt;5%), rectal hemorrhage (2% to &lt;5%), skin carcinoma (2% to &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (7%), increased serum alkaline phosphatase (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster (2% to &lt;5%), sepsis (2% to &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Ostealgia (9%), arthritis (5%), leg cramps (2% to &lt;5%), myalgia (2% to &lt;5%), neck pain (2% to &lt;5%), pathological fracture (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract (2% to &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria (6%), hydronephrosis (2% to &lt;5%), increased blood urea nitrogen (2% to &lt;5%), increased serum creatinine (2% to &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (8%), pharyngitis (8%), flu-like symptoms (7%), bronchitis (6%), asthma (2% to &lt;5%), epistaxis (2% to &lt;5%), sinusitis (2% to &lt;5%), pneumonia (4%), rhinitis (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Cyst (2% to &lt;5%), fever (2% to &lt;5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Decreased glucose tolerance, decreased hemoglobin, decreased white blood cell count, hepatic failure, hepatitis, hepatotoxicity, hypersensitivity (including angioedema and urticaria), increased serum ALT, increased serum AST, increased serum bilirubin, interstitial pneumonitis, interstitial pulmonary disease (most often at doses &gt;50 mg), pulmonary fibrosis, skin photosensitivity</p></div>
<div class="block coi drugH1Div" id="F141214"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to bicalutamide or any component of the formulation; use in women; pregnancy</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Patients with localized prostate cancer undergoing watchful waiting; children</p></div>
<div class="block war drugH1Div" id="F141196"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gynecomastia: Bicalutamide may cause gynecomastia or breast pain at higher (off-label) doses.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic: Anemia may occur with testosterone suppression; monitor CBC periodically as indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Cases of death or hospitalization due to severe liver injury have been reported (postmarketing); hepatotoxicity generally occurs within the first 3 to 4 months of treatment. Use with caution in moderate to severe hepatic dysfunction. Monitor transaminases (baseline and periodically); if clinical signs/symptoms suggestive of liver dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, dark urine, jaundice, right upper quadrant pain) occur, promptly monitor liver function tests; discontinue if patients have jaundice or ALT is &gt;2 × ULN.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Angioneurotic edema and urticaria have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Interstitial lung disease: Interstitial lung disease has been reported rarely (including fatalities) although mostly at dosages greater than what is recommended; promptly evaluate any worsening of respiratory symptoms (eg, dyspnea, cough and fever).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine 2010). Androgen deprivation therapy may cause prolongation of the QT/QTc interval (Garnick 2004); evaluate risk versus benefit in patients with congenital long QT syndrome, heart failure, frequent electrolyte abnormalities, and in patients taking medication known to prolong the QT interval. Correct electrolytes prior to initiation and consider periodic electrolyte and ECG monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">• Decreased bone mineral density: Prolonged use of antiandrogen therapy is associated with decreased bone mineral density and an increased risk of osteoporosis and fracture (Smith 2003); alcohol abuse, familial history of osteoporosis, and/or chronic use of drugs capable of decreasing bone mass (eg, corticosteroids) may increase risk. Evaluate risk carefully before initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: When used in combination with LHRH agonists, a loss of glycemic control and decrease in glucose tolerance has been reported in patients with diabetes; monitor.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in moderate to severe impairment; bicalutamide undergoes extensive hepatic metabolism. Limited data suggest excretion may be delayed in severe impairment leading to further drug accumulation. Consider periodic monitoring of liver function with prolonged therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Warfarin: Excessive prolongation of prothrombin time (PT) and INR days to weeks after bicalutamide initiation in patients previously stable on warfarin therapy have been reported (postmarketing). Serious bleeding events, including intracranial, retroperitoneal, and GI events (requiring blood transfusion and/or phytonadione [vitamin K]), occurred. Monitor PT/INR in patients on concomitant warfarin therapy, and adjust warfarin dose as necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anti-androgen withdrawal syndrome: Discontinue use immediately if disease worsens; decreased prostate specific antigen (PSA) levels and/or clinical improvement may be observed in some patients when antiandrogen therapy is held due to worsening of disease.</p></div>
<div class="block foc drugH1Div" id="F141207"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Casodex: 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p></div>
<div class="block geq drugH1Div" id="F141192"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F141216"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Bicalutamide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $16.47 - $18.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Casodex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $131.85</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866081"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Casodex: 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p></div>
<div class="block adm drugH1Div" id="F141211"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Dose should be taken at the same time each day, either in the morning or in the evening. May be administered with or without food. Treatment for metastatic cancer should be started concomitantly with an LHRH analogue.</p></div>
<div class="block hazard drugH1Div" id="F49104433"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]). </p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>
<div class="block use drugH1Div" id="F141210"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic:</b> Treatment of stage D<sub>2</sub> metastatic prostate cancer (in combination with an LHRH agonist)</p>
<p style="text-indent:-2em;margin-left:2em;">Limitation of use: Bicalutamide 150 mg daily is not approved for use alone or with other treatments</p></div>
<div class="block off-label drugH1Div" id="F25721949"><span class="drugH1">Use: Off-Label: Adult</span><p>Locally advanced prostate cancer (monotherapy)</p></div>
<div class="block mst drugH1Div" id="F7999083"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bicalutamide may be confused with apalutamide, enzalutamide, flutamide, nilutamide.</p>
<p style="text-indent:-2em;margin-left:4em;">Casodex may be confused with Kapidex [DSC]</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Casodex [US, Canada, and multiple international markets] may be confused with Capadex brand name for propoxyphene/acetaminophen [Australia, New Zealand]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298862"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F6218454"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: Bicalutamide may increase the serum concentration of Astemizole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: Bicalutamide may increase the serum concentration of Cisapride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Antiandrogens may diminish the diagnostic effect of Flotufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of these therapies on the performance of flotufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Antiandrogens may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact on the performance of gallium Ga 68 PSMA-11 (gozetotide) is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Antiandrogens may diminish the diagnostic effect of Piflufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of these therapies on the performance of piflufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: Bicalutamide may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Bicalutamide may increase the serum concentration of Vitamin K Antagonists. Specifically, free concentrations of the vitamin K antagonists may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095587"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and findings in animal reproduction studies, bicalutamide may cause morphological changes in spermatozoa, inhibit spermatogenesis, and impair male fertility. Males with female partners of reproductive potential should use effective contraception during therapy and for 130 days after the last dose.</p></div>
<div class="block pri drugH1Div" id="F2874397"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Bicalutamide is contraindicated for use in women, including pregnant women.</p></div>
<div class="block brc drugH1Div" id="F2874023"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if bicalutamide is present in breast milk. Use is contraindicated in women.</p></div>
<div class="block mop drugH1Div" id="F141205"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Periodically monitor CBC, ECG, echocardiograms, serum testosterone, luteinizing hormone, and prostate specific antigen (PSA). Liver function tests should be obtained at baseline and repeated regularly during the first 4 months of treatment, and periodically thereafter; monitor for signs and symptoms of liver dysfunction. Monitor blood glucose in patients with diabetes. If initiating bicalutamide in patients who are on warfarin, closely monitor prothrombin time and INR. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring for patients with prostate cancer: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; baseline and serial ECGs are recommended in patients at risk of QTc prolongation during androgen deprivation therapy (ADT); estimate 10-year cardiovascular disease risk in patients without cardiovascular disease at baseline; assess cardiovascular risk annually during ADT (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F141195"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Bicalutamide is a pure nonsteroidal androgen receptor inhibitor, specifically a competitive inhibitor for the binding of dihydrotestosterone and testosterone; prevents testosterone stimulation of cell growth in prostate cancer</p></div>
<div class="block phk drugH1Div" id="F141213"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed; unaffected by food</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 96%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic; glucuronidation and oxidation of the R (active) enantiomer to inactive metabolites; the S enantiomer is inactive</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Active enantiomer: ~6 days (~10 days in severe hepatic impairment)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Active enantiomer: ~31 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine and feces</p></div>
<div class="block phksp drugH1Div" id="F51154020"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The half-life is increased ~76% (to ~10 days) in patients with severe liver disease.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F141218"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Casodex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Androxinon | Bicalutamida dosa | Bicalutamida gp | Bicalutamida ima | Bicalutamida kemex | Bicalutamida Kilab | Bicalutamida servycal | Bicalutamida techsphere | Bicalutamida varifarma | Bicaprost | Bidrostat | Biolutam | Bitakebir | Bosconar | C3co | Casodex | Codebup | Dimalan | Gepeprostin | Liberprost | Lutamidal | Raffolutil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Androbloc | Bicalupel | Bicalutamid | Bicalutamid +Pharma | Bicalutamid actavis | Bicalutamid Arcana | Bicalutamid Bluefish | Bicalutamid Hexal | Bicalutamid Hikma | Bicalutamid Kabi | Bicalutamid Ranbaxy | Bicalutamid Ratiopharm | Bicalutamid Stada | Bicalutamid teva | Casodex</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-bicalutamide | Bicalide | Bicalox | Bicalutamide an | Bicalutamide Ranbxy | Bicalutamide-GA | Calutex | Cosamide | Cosudex</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Casodex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamide accord healthcare | Bicalutamide eg | Bicalutamide sandoz | Casodex</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Pms bicalutamide</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bicacon | Bicagratis | Bicalodex | Bicalutamide kabi | Bicusan | Calutide | Casodex | Yonistib</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamida | Bycal | Casodex | Gepeprostin | Lutamidal</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamid actavis | Bicalutamid Mepha | Bicalutamid orion | Bicalutamid Sandoz | Bicalutamid teva | Bicalutamid zentiva | Bicamed | Casodex</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Casodex | Pms bicalutamide</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamida | Bidrostat | Biolev | Casodex | Lutamidal</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Casodex | Zhao hui xian</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Androdex | Bicahet | Bicalex | Bicalida | Bicalutamida | Bicalutamida bicalier | Casodex | Hb oncoprost | Lutamidal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo Bicalutamid | Apotex Bicalutamid | Bicaluplex | Bicalutagen | Bicalutamid actavis | Bicalutamide Bluefish | Bicalutamide pharmacenter | Bicalutanorm | Bikalard | Binabic | Bjorgeina | Casodex | Glanuta | Lanbica</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Androcal | Bica Q | Bicadex | Bicalutam Esparma | Bicalutamid | Bicalutamid 1 A Pharma | Bicalutamid abz | Bicalutamid accord | Bicalutamid actavis | Bicalutamid AL | Bicalutamid Aristo | Bicalutamid Atid | Bicalutamid axcount | Bicalutamid basics | Bicalutamid beta | Bicalutamid Billix | Bicalutamid biomo | Bicalutamid Bluefish | Bicalutamid CT | Bicalutamid devatis | Bicalutamid dura | Bicalutamid esparma | Bicalutamid Fair Med | Bicalutamid Heumann | Bicalutamid Hexal | Bicalutamid medac | Bicalutamid puren | Bicalutamid Ratiopharm | Bicalutamid Sandoz | Bicalutamid Stada | Bicalutamid synthon | Bicalutamid tecnimede | Bicalutamid teva | Bicalutamid uropharm | Bicalutamid Winthrop | Bicalutamide accord | Bicalutamide teva | Bicalutin | Bicamed | Casodex | Eurobicalutamid | Ribocadex</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Bicalustad</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Bicalut | Bicalutamida | Bunide | Casodex | Casomax | Teoprin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamida | Bicloc | Calutol | Casodex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamid actavis | Bicalutamide accord | Bicalutamide grindeks | Casodex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Becalocyrl | Bicalutamide pharmacare | Biluron | Casodex | Malignomide</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamida | Bicalutamida accord | Bicalutamida Actavis | Bicalutamida Almus | Bicalutamida Apotex | Bicalutamida belmac | Bicalutamida Bluef | Bicalutamida Cinfa | Bicalutamida Combix | Bicalutamida Davur | Bicalutamida Edigen | Bicalutamida Mabo | Bicalutamida Mylan | Bicalutamida Normon | Bicalutamida Pensa | Bicalutamida Pharmagenus | Bicalutamida sandoz | Bicalutamida stada | Bicalutamida Tecni | Bicalutamida Winthrop | Bicamylan | Bicarbex | Biobica | Casodex | Ormandyl | Pencial | Probic | Saveprost | Wibical</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Casodex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamid Alternova | Bicalutamid orion | Bicalutamid Ranbaxy | Bicalutamid Ratiopharm | Bicalutamid Sandoz | Bicalutamide accord | Bicalutamide Bluefish | Bicalutamide grindeks | Bicavan | Bidanil | Bikalutamidi Medac | Casodex | Kandex | Skylutamide</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamide actavis | Bicalutamide almus | Bicalutamide Alter | Bicalutamide Arrow | Bicalutamide biogaran | Bicalutamide cristers | Bicalutamide eg | Bicalutamide evolugen | Bicalutamide Intas | Bicalutamide kabi | Bicalutamide Mylan | Bicalutamide phr | Bicalutamide Qualimed | Bicalutamide Ranbaxy | Bicalutamide ratiopharm | Bicalutamide sandoz | Bicalutamide Zydus france | Casodex | Ormandyl</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Casodex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Apex | Bicadex | Bicalut | Bicalutamide generics | Bicalutamide teva | Bicalutamide/Medac | Bicalutamide/Specifar | Bicamide | Bicaprol | Bicatin | Bikalen | Biludex | Bilumide | Casodex | Encalor | Lutrak | Omidex | Ormandyl | Procadex | Procure | Verodex | Zarmol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-bicalutamide | Casodex</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Bicaprox | Biclutide | Bikalis | Bikalutamid JGL | Bilumid | Bixalan | Casodex | Kalufar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamid Amite | Bicalutamid Cremum | Bicalutamid Kabi | Bicalutamid Mentor pharma | Bicalutamid Ratiopharm | Bicalutamid Sandoz | Bicalutamide Bluefish | Bicalutamide pharmacenter | Bicalutatam | Bicatlon | Bilutamid | Binabic | Calumid | Capro | Casodex | Grommar | Lanbicamid | Sanotamid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bicastra | Biluron | Casodex | Diproca</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bicalinn | Bicalutamide teva | Biluta | Casodex | Casomide</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Casodex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Admide | Androblok | Avobi | Bical | Bicalon | Bicalpro | Bicatero | Biprosta | Calbimide | Caludec | Caluran | Calutide | Cassotide | Castramid | Cosalon | Netide | Samtide | Tabi | Utamide</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamide actavis | Bicalutamide Ahcl | Bicalutamide Blf | Bicalutamide Chiesi | Bicalutamide Crinos | Bicalutamide Doc | Bicalutamide eg | Bicalutamide Hik | Bicalutamide Mylan | Bicalutamide Ranbaxy | Bicalutamide ratiopharm | Bicalutamide sandoz | Bicalutamide Sun | Bicalutamide tecnimede | Casodex | Igredex | Lutamid | Safedex | Satrexem</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Androdex | Bicamide | Casodex | Clamudex</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamide Amel | Bicalutamide Aska | Bicalutamide DK | Bicalutamide dsep | Bicalutamide F | Bicalutamide Jg | Bicalutamide JMA Engineering | Bicalutamide KN | Bicalutamide Meiji | Bicalutamide Mylan | Bicalutamide NK | Bicalutamide NP | Bicalutamide Ohara | Bicalutamide pfizer | Bicalutamide sandoz | Bicalutamide Sawai | Bicalutamide SN | Bicalutamide Taiyo | Bicalutamide Tatumi | Bicalutamide TCK | Bicalutamide Towa | Casodex</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bicatero | Bypro | Caltam | Casodex | Prostaglob</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bicadex | Bicalu | Bicalude | Bicarud | Bicaso | Cadex | Calutami | Casdel | Casobit | Casodex | Ckd bicalutamide | Procadex | Procalin | Prosaid | Teva bicalutamide</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Casodex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo-bicalutamide | Bicalutamide biogaran | Bicamide | Bypro | Prosmide</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bicalan | Bicalutami accord | Bicalutamide accord | Bicalutamide grindeks | Bicalutamide teva | Calumid | Casodex | Sapro</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamid Ratiopharm | Bicalutamide eg | Casodex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Arecloc | Bicalan | Bicalutamide actavis | Bicalutamide grindeks | Bicalutamide teva | Calumid | Casodex | Sapro</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamide cooper | Bicalutamide Gt | Casodex | Protadex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Advanpro | Apotector | Bedara | Bicalem | Bicalutamid teva | Bicalutamida | Bicalutamida ultra | Bicotexida | Bilumiv | Calutol | Camifhal | Casdrogen | Casodex | Damitala | Duodox | Festeride | Kabicalex | Redlion | Treumida | Tulac | Venibyk | Zuprot</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Bical | Bicalox | Calumid | Casodex</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamide sandoz | Casodex | Isobase</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamide accord | Bicalutamide Aurobindo | Bicalutamide hikma | Bicalutamide pch | Bicamedica | Biluron | Casodex | Casodex 50</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamid Actav | Bicalutamid orion | Bicalutamid Sandoz | Bicalutamide Bluefish | Bicalutamide teva | Bikalutamid Medac | Casodex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bicalaccord | Bicalox | Binarex | Calutex | Calutide | Casodex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bical | Bicalutamida | Casodex | Lutamidal | Tamida</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bicadex | Bicamide | Bicapros | Bicatero | Biomedis bicalutamide | Calubia | Casodex | Celobic 50 | Mpl bica | Prosmide</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bicalox | Bicalutacal | Bicamide | Bitamid | Calutide | Casodex | Cosalon | Geperprostin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamid Mylan | Bicalutamide accord | Bicalutamide Apotex | Bicalutamide Polpharma | Binabic | Calubloc | Casodex | Prostide</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Casodex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamida accord | Bicalutamida germed | Bicalutamida Hikma | Bicalutamida kabi | Bicalutamida mepha | Bicalutamida pharmakern | Bicalutamida sandoz | Bicalutamida stada | Bicalutamida teva | Casodex | Ormandyl</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamida DF | Bicalutamida dosa | Bicalutamida imedic | Bicalutamida intas | Bicalutamida lkm | Bicalutamida quimfa | Bicalutamida varifarma | Bicalutamida vmg | Bidrostat | Bilumiv | Bitakebir | Casodex | Codebup | Finaband | Lutamidal</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Casodex | Lutam</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamid terapia | Bicalutamida accord | Bicalutamida alvogen | Bicalutamida atb | Bicalutamida kabi | Bicalutamida ranbaxy | Bicalutamida sandoz | Bicatlon | Calumid | Casodex | Yonistib</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Androbloc | Androblock | Balutar | Bicalutamid | Bicalutamid Kabi | Bicalutamid teva | Bicalutamide canon | Bicalutamide kabi | Bicalutamide sandoz | Bicalutera | Bicaprost | Bikana | Bilumid | Calumid | Casodex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-bicalutamide | Casodex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Baculamyl | Bicacta | Bicalustad | Bicalutamid Sandoz | Bicalutamide accord | Bicalutamide Bluefish | Bicalutamide Orion | Bicalutamide ratiopharm | Bicalutamide teva | Bictamid | Bikalutamid Actavis | Bikalutamid ebb | Bikalutamid Medac | Bikalutamid Ranbaxy | Bikalutamid Sun | Casodex | Nycolutamid</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bicalox | Bicamed | Casodex | Talum</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bikalutamid Lek | Bikalutamid Teva | Casodex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bicacel | Bicalutamid actavis | Bicalutamid teva | Bicalutamide Medac | Bicalutamide pharmacenter | Bicalutamide Sanomed | Bicatleon | Bicusan | Bikalutamid Accord | Binabic | Caprodez | Casodex | Glanuta</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamide sandoz | Bicalutamide teva | Bypro | Calumid | Casodex | Pms bicalutamide</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bicamide | Casodex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Calux | Casodex | Casomid | Procalut</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Abicalutamide | Bicalutamide teva | Bicatero | Bypro | Casodex | Pms bicalutamide</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Areclok | Areklok | Bicalutamide genepharm | Bicalutera | Bicatero | Biculid | Calumid | Casodex | Vistamid</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Bicatero | Casodex</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamida | Bicalutamida delta farma | Bicalutamida eurofarma | Bicalutamida Glenmark | Bicamida | Bidrostat | Calutol | Casodex | Euprost | Liberprost | Lutamidal | Neopros</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bicalutamida | Calutol | Casodex</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord bicalutamid | Anandroca | Bicadex | Bicalox | Bicalutamide accord | Caloxa | Casodex | Sandoz Bicalutamid | Spec bicalutamide | Tasdiam | Teva bicalutamide</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Bicatero</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Bicatero | Bypro | Casodex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25199761">
<a name="25199761"></a>Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/25199761/pubmed" id="25199761" target="_blank">25199761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zydus.1">
<a name="Zydus.1"></a>Bicalutamide [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals USA Inc; February 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ANI.1">
<a name="ANI.1"></a>Casodex (bicalutamide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AstraZeneca.1">
<a name="AstraZeneca.1"></a>Casodex (bicalutamide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Garnick.1">
<a name="Garnick.1"></a>Garnick MB, Pratt CM, Campion M, et al. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix [abstract]. <i>J Clin Oncol</i>. 2004;22(14S):4578.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Iversen.1">
<a name="Iversen.1"></a>Iversen, P, Johansson JE, Lodding P, et al. Bicalutamide (150 mg) Versus Placebo as Immediate Therapy Alone or as Adjuvant to Therapy With Curative Intent for Early Nonmetastatic Prostate Cancer: 5.3 Year Median Followup from the Scandinavian Prostate Cancer Group Study Number 6. <i>J Urol</i>. 2004;172(5, pt 1):1871-1876.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124128">
<a name="20124128"></a>Levine GN, D’Amico AV, Berger P, et al. Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association. <i>Circulation</i>. 2010;121:831-838.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/20124128/pubmed" id="20124128" target="_blank">20124128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17404365">
<a name="17404365"></a>Loblaw DA, Virgo KS, Nam R, et al. Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline. <i>J Clin Oncol</i>. 2007;25(12):1596-1605.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/17404365/pubmed" id="17404365" target="_blank">17404365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16430622">
<a name="16430622"></a>McLeod DG, Iversen P, See WA, et al. Bicalutamide 150 mg Plus Standard Care vs Standard Care Alone for Early Prostate Cancer. <i>BJU Int</i>. 2005;97(2):247-254.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/16430622/pubmed" id="16430622" target="_blank">16430622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16753373">
<a name="16753373"></a>McLeod DG, See WA, Klimberg I, et al. The Bicalutamide 150 mg Early Prostate Cancer Program: Findings of the North American Trial at 7.7-Year Median Followup. <i>J Urol</i>. 2006;176(1):75-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/16753373/pubmed" id="16753373" target="_blank">16753373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7538237">
<a name="7538237"></a>Schellhammer P, Sharifi R, Block N, et al. A Controlled Trial of Bicalutamide Versus Flutamide, Each in Combination With Luteinizing Hormone-Releasing Hormone Analogue Therapy, in Patients With Advanced Prostate Cancer. Casodex Combination Study Group. <i>Urology.</i> 1995;45(5):745-752.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/7538237/pubmed" id="7538237" target="_blank">7538237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9301693">
<a name="9301693"></a>Schellhammer PF, Sharifi R, Block NL, et al. Clinical Benefits of Bicalutamide Compared With Flutamide in Combined Androgen Blockade for Patients With Advanced Prostatic Carcinoma: Final Report of a Double-Blind, Randomized, Multicenter Trial. Casodex Combination Study Group. <i>Urology</i>. 1997;50(3):330-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/9301693/pubmed" id="9301693" target="_blank">9301693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12548577">
<a name="12548577"></a>Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. <i>Cancer</i>. 2003;97(3)(suppl):789-795.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bicalutamide-drug-information/abstract-text/12548577/pubmed" id="12548577" target="_blank">12548577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9154 Version 286.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
